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Abstract
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Brain tumor biopsies that are routinely performed in clinical settings significantly aid in diagnosis
and staging. The aim of this study is to develop and evaluate a methodological image-guided
approach that would allow for routine sampling of glioma tissue from orthotopic mouse brain
tumor models. A magnetic resonance imaging-guided biopsy method is presented to allow for
spatially precise stereotaxic sampling of a murine glioma coupled with genome-scale technology
to provide unbiased characterization of intra- and intertumoral clonal heterogeneity. Longitudinal
and multiregional sampling of intracranial tumors allows for successful collection of tumor biopsy
samples, thus allowing for a pathway-enrichment analysis and a transcriptional profiling of RNA
sequencing data. Spatiotemporal gene expression pattern variations revealing genomic
heterogeneity were found.
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Introduction
Glioblastoma (GBM) is the most common and aggressive intracranial tumor in adults.
Despite decades of research, survival remains dismal, with a mean survival time of 15
months and a mean 5-year survival rate of < 10% (1-3). The standard therapy consists of
maximal safe surgical resection, followed by radiation and then chemotherapy with
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temozolomide, and this protocol has changed very little since its inception (2). Although
many patients initially respond, GBM inevitably recurs in most patients (1).
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Given its poor prognosis, GBM is a perfect candidate for targeted therapy using precision
medicine; thus, understanding the genetic profile of GBM is vital. However, known spatial
and temporal tumor heterogeneity is recognized as a significant obstacle for accurate
diagnosis impeding the use of targeted therapies. GBM is among the first tumor types for
which in-depth genomic analyses were performed (4), and integrated genomic analyses
performed in a large cohort of patients uncovered complex clonal heterogeneity (4),
intertumoral heterogeneity (5-10), and intratumoral heterogeneity (11-14). Recent studies
have revealed that customized treatments targeting specific mutations may not be efficacious
in altering patient outcomes (15). Although in this case the cause of treatment failure is
unclear, previous studies have shown that between 67% and 91% of posttreatment failures
no longer harbored the target mutation (16, 17). This is probably because of clonal
expansion of cells outside the targeted mutation. GBM is also known to change its molecular
signature with treatment (18). These findings reflect the highly dynamic genetic evolution
present in GBM, confounding the elucidation of its complete genetic landscape.
Multiregional tumor sampling is ideal in GBM and other tumor types, but it is often
impractical and potentially risky for routine clinical application (19, 20). Furthermore, tumor
sampling during different treatment phases is often clinically unindicated. However, precise
mechanisms underlying tumor heterogeneity and its functional significance can be evaluated
in preclinical models for discovery of driver mutations, discovery of mechanisms of drug
resistance, identification of genetic and imaging biomarkers, and development of clonespecific cancer therapies.
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Here, we devised and successfully showed a magnetic resonance imaging (MRI)-guided
stereotactic biopsy method for isolation and functional profiling of tumoral heterogeneity to
assess temporal and geographical genomic variations during disease progression in an intact
murine GBM model. Longitudinal tumor biopsy samples were obtained at different stages of
tumor growth and in spatially distinct locations. RNA sequencing (RNA-Seq) of biopsy
tissue showed unique temporal and spatial gene expression patterns.

Methods
Mouse Strains
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The p53 mutant GBM mouse model was obtained from Dr. Yuan Zhu Children's National
Medical Center (Washington DC). The genotype and maintenance of the strain have been
described previously (21). Animal experiments were approved by the University Committee
on the “Use and Care of Animals” (UCUCA) at the University of Michigan.
MRI Acquisition
Mice were anesthetized using a 1%–2% isofluorane–air mixture throughout the duration of
the MRI experiment. Then, 5 minutes before anesthesia administration, 50 μL of 0.5M
gadolinium (Gd) – diethylenetriaminepentaacetic acid (DTPA) (Magnevist; Bayer
Healthcare Pharmaceuticals) was injected intraperitoneally. Once anesthetized, mice were
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securely fastened in the animal handling MRI cradle with a bite bar and stererotactic
bilateral ear bars. An external fiducial marker consisting of Gd contrast agent was secured to
the coil ∼ 1 cm left of the mouse skull. MRI scanning was performed using a 7 T Direct
Drive MR system (Agilent, CA) using a volume radiofrequency transmit coil and a 2channel fixed-tuned actively decoupled surface receive coil with the mouse handling cradle
including bilateral ear bars and a bite bar for securing the mouse head (Rapid MR
International). During MRI, heated air was introduced into the magnet bore (World Precision
Instruments) to maintain animal body temperature. T1-weighted spin echo images were
acquired for each animal using a spin echo sequence with the following parameters:
repetition time/echo time = 510/15 milliseconds, field of view = 20 × 20 mm2, matrix size =
128 × 128, slice thickness = 500 μm, number of slices = 25 interleaved sections, and 2 signal
averages per phase encode step.
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MRI Biopsy Validation Study
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Phantoms were constructed using agarose gel blocks. Bubbles with varying volumes of air
(5, 10, and 20 μL) were injected into the gel before it solidified using a Hamilton syringe.
The MRI radiofrequency coil bed with an associated fiducial marker was modified to allow
for secure attachment to a Kopf stereotactic device to provide for a consistent and
reproducible coordinate system. MRI-guided biopsy was performed on the gel blocks as
described below to validate targeting accuracy. Instead of extracting “tissue” (eg, gel), we
injected a 1:10 dilution of 0.5M Gd-DTPA (Magnevist) into the agarose gel at the calculated
location of the intended target volume (eg, air bubble). If the air bubble was successfully
filled with the contrast agent, the air would be displaced and a bright signal in the T1
magnetic resonance (MR) image would be used to verify success versus failure. Gel-based
target biopsies were performed on 15, 12, and 12 bubbles with 5-, 10-, and 20-μL volumes,
respectively. The accuracy of the method was determined as follows: [(success)/(total
number of target volumes)] × 100%. Success was determined as the ability of the biopsy
needle to completely fill the target volume as determined by MRI.
Intracranial Biopsy Procedure
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After acquisition of prebiopsy MR images, the mouse was anesthetized with a ketamine/
xylazine (0.1/0.02 mg/kg) mixture. The tumor was localized with 3-dimensional (3D)
Cartesian coordinates on the basis of the distance from the external fiducial marker. The coil
was secured to a coil-holder with an attached Kopf stereotactic coordinate system. The
mouse was prepped for surgical biopsy and the eyes were protected using eye lubrication.
The scalp was sterilized with a topical antiseptic solution and allowed to dry. A 1.5-cm
longitudinal incision was made across the midline beginning just posterior to the nasion. The
scalp and pericranium were gently retracted and the skull was exposed with cotton-tip
applicators. A drill was attached to the stereotactic system (Foredom K-1070 with MH-170
drill with stereotaxic attachment-Model 1474; with Kyocera #70 105-0280.400 drill bits).
The attached drill was used to localize the skull burr hole site based on the MRI-determined
Cartesian coordinates. After the burr hole was made, a fine aspiration needle (Inrad Model
54722) was secured to the stereotactic instrument and placed into the burr hole. The needle
was then advanced to the MRI-determined depth at the proximal/superior edge of the tumor.
The inner cannula was removed and the needle was advanced toward the center of the tumor.
Tomography. Author manuscript; available in PMC 2017 May 25.
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The needle was attached to a mini-bore extension set (Abbott 32072) connected using a
locking aspiration syringe. A syringe was used to withdraw with 2.5 mL of pressure for 3
seconds before the pressure was re-equalized, and the needle was withdrawn from the skull.
The biopsy sample was collected in a sterile 2-mL centrifuge tube. Samples were either snap
frozen or manually dissociated and cultured at 37°C.
After the biopsy, the burr hole was covered with bone wax (#W810, Ethicon), and the
incisions were approximated and closed with Vetbond (#1469SB, Vetbond). To minimize
pain, 100 μL (1 mg/mL) of Rimadyl (Pfizer Animal Health) was subcutaneously
administered following completion of the surgical procedure. The mouse was kept secured
in the coil holder and the MRI was repeated. T1-weighted images were acquired as
described above to confirm the accuracy of the biopsy and to rule out significant
complications.
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A second late-stage biopsy was performed when the tumor volumes reached ∼100 μL. Two
distinct biopsy locations were identified and similar biopsy procedures were carried out as
described above. The notation Mx[y] was used to denote mouse number [x] and tumor
biopsy sample number [y]. At the conclusion of the final biopsy and MR scans to confirm
biopsy locations, the animals were sacrificed.
RNA-Seq
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Tumor biopsy tissues were used for RNA extraction. Total RNA was extracted using
TRIzolä (#10296010; Life Technologies) and ethanol precipitation as per the manufacturer's
instructions. RNA-Seq library preparation and sequencing was completed by DNA
sequencing core at the University of Michigan. Specifically, the RNA library was prepared
with NEBNext® rRNA Depletion Kit (#E6310L, NEB). Further, 30–45 million 50nt-singleend reads were obtained from each sample with an estimated 20–30× sequencing depth.
RNA-Seq Data Analysis
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Single-end reads of RNA-Seq data were mapped to the mouse transcriptome (GRCm38.p4/
mm10) using BWA, duplicate reads were marked by Picard, and base quality scores were
recalibrated using GATK, by referring to the PRADA pipeline (22), followed by proceeding
with the mapped reads to calculate the read counts and RPKM (reads per kilobase of
transcript per million mapped reads) values for 39,017 expressed genes (Ensembl Gene ID)
using UCSC/mm10/ensGene transcript database, with associated gene names annotated
based on Ensembl genome assembly (Biomart). Differential expression of genes was
calculated by applying quantile-adjusted conditional maximum likelihood method that fits
read counts with negative binomial models and obtains dispersion estimates, followed by an
exact test to determine differential expressions based on false discovery rate (FDR ∼
adjusted P value) (23). Genes were considered to be differentially expressed when the
change was greater than 1.5-fold, and the adjusted P value (FDR) was <0.05%.
Pathway and network analyses of differentially expressed genes in early- versus late-stage
biopsies were performed using ingenuity pathway analysis (IPA) software (Qiagen). The
molecule activity predictor in IPA was used to predict the upstream or downstream
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activation or inhibition of a given pathway. The P value of the enrichment score was used to
evaluate the significance of the overlap between observed and predicted gene sets. All
statistical analyses were performed and graphs were obtained under R (version 3.2.3)
environment.
Tumor purity was evaluated on RPKM (reads per kilobase of transcript per million mapped
reads) values of gene expression profiling using ESTIMATE, based on the enrichment of
gene signatures in stromal and immune cells (24). The molecular classification of samples
was performed using ssGSEA.

Results
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To enable temporal and geographical multisampling of tumor tissue in a murine GBM
model, we devised a biopsy apparatus (Figure 1A). For tumor localization, a 3D Cartesian
coordinate diagram with external fiducial markers was used to guide biopsy (Figure 1B). To
validate the stereotactic biopsy efficiency and accuracy, an MR phantom consisting of agar
gels was developed. Three different volumes of air bubbles (void spaces) were used as
representative tumor sizes. Once the locations of the voids were determined by MRI within
the 3D coordinate system on the basis of the distance from the external fiducial marker, Gd
was stereotactically injected into spatially distinct voids via biopsy needles. MRI T1 images
were taken before and after Gd injection to determine the accuracy of the biopsy method
(Figure 1C). Further, 12–15 mock biopsies were performed for each size, and the accuracy
was shown to be 100, 92, and 73% at volumes of 20, 10, and 5 μL, respectively (Figure 1D).
These results show that sampling of tumors as small as 5 μL can be routinely achieved with
a high degree of accuracy using this MRI-guided biopsy method.
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Next, we demonstrated this method for stereotactic MRI-guided multiregional sampling of
spontaneous murine p53 mutant GBM tumors with tumor volumes of 10-20 μL. Animals
were secured in a stereotactic biopsy station (Figure 1A), and the tumor was localized on the
basis of the distance from the external fiducial marker (Figure 1B) using MRI. MR images
were easily acquired both before and after stereotactic biopsy sampling (as depicted in
Figure 2A) by transferring the MRI animal cradle to a holder with an attached stereotactic
coordinate system. After surgical preparation, the Cartesian coordinate system was used to
localize the tumor, and a fine aspiration needle attached to an articulating apparatus was
used to withdraw the biopsy tissue specimen. The tissue was either snap frozen for RNA
extraction or manually dissociated for cell culture (data not shown). T1-weighted MRI was
repeated after biopsy to confirm the accuracy of the biopsy and the sampling location. Three
p53 mutant GBM animals were used to perform an early-stage biopsy. Further, 2
geographically distinct locations were sampled during the late-stage biopsies for each animal
at a tumor volume of ∼100 μL (Figure 2, B and C) to investigate intertumoral genomic
heterogeneity.
The analysis of spatiotemporal genomic heterogeneity was accomplished by RNA-Seqbased expression profiling of early- and late-stage biopsies, which revealed distinct temporal
and spatial gene expression patterns. We compared both early- and late-stage biopsies of 3
individual mice, and we depicted the top 10 genes upregulated (Figure 3A) and
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downregulated (Figure 3B) in late-stage biopsies. Pathway-enrichment analysis of
differentially expressed genes during tumor progression further identified unique molecular
patterns. Upregulated and down-regulated pathways in late- versus early-stage biopsies are
depicted (Figure 3C). Overall, the pathway-enrichment analysis of differentially expressed
genes in early- versus late-stage biopsy samples showed significant differences in molecular
patterns during tumor progression. Moreover, spatially varying differences in expressed
genes were also observed in late-stage tumors, revealing that intertumoral heterogeneity in
this GBM mouse model could be detected using this method.
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Transcriptional profiling of GBM has been previously performed in large-scale clinical
studies, and heterogeneous genotypes consisting of subclones with varying tumorigenic,
proliferative, differentiation, and drug responsiveness have been shown (4, 5, 18). To
identify whether such spatial (geographical) gene expression patterns were present in a
preclinical p53 mutant GBM model, 2 spatially distinct locations of late-stage tumors using
the aforementioned criteria and IPA pathway analysis were compared (Figure 3D).
Interestingly, transcription factor OTX2 was differentially regulated between the 2 spatially
distinct regions. OTX2 has been implicated as an oncogene in medulloblastoma where it is
highly expressed and amplified in a subset of these tumors (25). OTX2 regulates cell cycle
and differentiation, and its regulated genes may serve as potential therapeutic targets (25).
Differentially regulated pathways between regions are depicted (Figure 3E). Up- and/or
downregulated genes were found, and although detailed studies need to be conducted to
investigate the roles of each gene in tumor growth and survival, some genes identified have
been indicated to play a role in overall patient survival and tumorigenesis. For example,
Ighg1 has been shown to affect overall survival in GBM patients, indicating that it may be
associated with more aggressive tumor characteristics in the late stages of tumor growth.
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Discussion
Molecular characterization of tumors to guide treatment selection is hampered by intratumor
heterogeneity (19, 26). Longitudinal and multifocal monitoring of clonal dynamics may
provide for improved patient care (19). In this study we devised an experimental approach
for image-guided tumor sample acquisition from isolated GBM biopsies for sequencing to
enable comparative analyses of gene expression patterns and tumor growth. This method
allowed for longitudinal tissue sampling over time and in geographically specific regions to
gain further insight into the mechanisms of heterogeneity, thus allowing for linking
phenotypic and genomic characteristics.
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Although phenotypic analyses are not shown here, neurosphere cultures may also be
established from GBM biopsies (data not shown). Single-cell expansion and functional
assays may be performed from these biopsies and are a topic for future investigations.
Although cell to cell differences were not investigated in this study, this approach would also
allow for single-cell isolation and investigation of clonal heterogeneity. These studies can
easily be expanded to include DNA extraction and the analysis of genetic variations by
exome or deep sequencing approaches. We believe that these types of sequencing analyses
may aid in the identification of genetic and imaging biomarkers.
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Currently, MRI-based stereotactic intracranial procedures are routine in clinical practice.
However, an accurate intracranial biopsy technique has not been shown in mouse models.
Here, we established an innovative and accurate stereotactic image-guided murine biopsy
method that is capable of accurate and repeated biopsy collection from an individual animal.
Tissues collected can be used to investigate genomic dynamics during disease progression
and modulation during treatment intervention. Spatial and temporal variations in the
molecular landscape of preclinical models may provide unique insights into the development
and interrogation of novel therapeutic strategies. This information provides opportunities for
evaluating genomic responses during treatment to gain a further biological understanding of
drug/target modulation and mechanisms of drug resistance and clonal evolution. Elucidation
of the precise mechanisms of existing or emerging tumor heterogeneity and its functional
significance in preclinical models provides opportunities to discover driver mutations,
emergence of drug resistance, identification of genetic and or imaging biomarkers, and
development of clone-specific cancer therapies. Here, we devised a method to isolate and
functionally profile intratumoral heterogeneity by using MRI-guided biopsies to assess
temporal and geographical differences during disease progression in a murine GBM model.
We successfully collected tumor biopsy samples at different stages of tumor growth and
individual locations. RNA-Seq results showed unique temporal and spatial gene expression
patterns in GBM. This approach may allow for new opportunities for assessing tumor tissue
samples from discrete spatial locations over time to improve our understanding of the role of
spatial heterogeneity and genomic instability in adaptation mechanisms and therapy
resistance. In the future, this approach may be adapted to investigate treatment-induced
changes and adapted to study other primary and metastatic tumor types. In summary, the
combination of MRI-guided tumor sampling with advanced genome sequencing can
facilitate identification of mechanisms leading to heterogeneity and development of
clinically useful measures of heterogeneity, which may guide identification of new
therapeutic strategies.
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GBM

Glioblastoma

MRI

magnetic resonance imaging

Gd

gadolinium

MR

magnetic resonance

FDR

false discovery rate

IPA

ingenuity pathway analysis

3D

3-dimensional

RNA-Seq

RNA sequencing
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Instrument setup and optimization used for image-guided biopsy of murine intracranial
tumors. Magnetic resonance imaging (MRI)-guided stereotactic biopsy station (A). MRIcoordinate diagram of stereotactic biopsy with fiducial marker to guide biopsy (B).
Magnetic resonance (MR) gel phantom with intended stereotactic biopsy site denoted
(circle) along with the location of the fiducial marker (arrow) (C). Graphical representation
of biopsy accuracy using MR phantom (D). Target biopsy success/number of attempts: 5 μL:
11/15 (73%); 10 μL: 11/12 (92%); 20 μL: 12/12 (100%).
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Figure 2.

MRI images and 3-dimensional (3D) rendering shows location and time of multiple biopsies
from p53-deficient glioma models. Stereo-tactic biopsy pre- and postbiopsy shown in 2D
and 3D (A). MRI-based volumetric analysis of intracranial tumor growth (B). Arrows
indicate time points when early- and late-stage biopsies were taken. Postbiopsy T1-weighted
MRI shows an early-stage glioma biopsy (left panel) and 2 late-stage biopsy locations (right
panel; C). Tumor volume extents are delineated with a red-dotted line.
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Figure 3.

RNA-sequencing (RNA-Seq)-based expression profiling of early- and late-stage biopsies
reveals distinct temporal and spatial gene expression patterns. The top 10 genes (A)
upregulated and downregulated (B) in late-stage biopsies are displayed. Differential
expression of genes was calculated. Pathway and network analyses of differentially
expressed genes performed using ingenuity pathway analysis (IPA) software (C). The
molecule activity predictor in IPA was used to predict the upstream or downstream
activation or inhibition of a given pathway. Spatial gene expression patterns were identified
by comparing 2 different locations of late-stage tumors (location 1 vs. 2) using the
aforementioned criteria (D) and IPA pathway analysis (E). Nomenclature: Mx[y] denotes
mouse number [x] and tumor biopsy sample number [y].
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